Company intelligence / Profile preview

Denali Capital Acquisition Corp.

Palo Alto, California, USA

Ownership: Private
Development stage: Other

Overview

Denali Capital Acquisition Corp. is a special purpose acquisition company (SPAC) focused on healthcare/pharmaceutical sector transactions. As of August 2025, it has announced a proposed business combination with Semnur Pharmaceuticals (majority-owned by Scilex Holding), a developer of non-opioid pain management products. Upon merger completion, the combined entity will be renamed Semnur Pharmaceuticals, Inc., with a focus on innovative therapies for pain and possible expansion into neurodegenerative and cardiometabolic diseases.[4][6]

Industry: Investors

Partnerships

Semnur Pharmaceuticals (proposed merger)Scilex Holding Company (Semnur's parent)

Beyond the preview

Go deeper on Denali Capital Acquisition Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Denali Capital Acquisition Corp..

Explore the full profile